Loading
Virus-based Gene Therapy Research / CRISPR and Genetic Engineering · Journal article
Frontiers in Genome Editing · September 10, 2026
A consensus or society position rather than new primary data.
This is a structured narrative review synthesizing clinical and preclinical evidence on CRISPR-Cas9 therapeutics across oncology and inherited genetic disorders. It documents early clinical successes (BCL11A editing in sickle cell disease and β-thalassemia, transthyretin reduction, visual improvements in CEP290-associated retinal disease) alongside significant translational barriers (off-target mutations, immune responses to Cas9 and vectors, tissue delivery challenges, and ethical concerns). The review identifies emerging alternatives (base editing, prime editing) but does not quantify efficacy or compare outcomes systematically.
Structured narrative literature review. Published clinical and preclinical studies on CRISPR-Cas9 therapeutics in oncology and inherited genetic disorders.. Intervention: CRISPR-Cas9 therapeutic approaches including ex vivo BCL11A editing, in vivo lipid nanoparticle delivery, subretinal AAV delivery, and CRISPR-engineered T cells..
Ex vivo BCL11A-enhancer editing showed fetal hemoglobin reactivation; most evaluable participants with sickle cell disease remained free of severe vaso-occlusive crises for prespecified period Most evaluable participants with transfusion-dependent β-thalassemia achieved sustained transfusion independence following BCL11A editing In vivo transthyretin protein level reductions achieved for transthyretin amyloidosis via lipid nanoparticle delivery
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians and researchers should recognize that CRISPR-Cas9 has demonstrated early clinical efficacy in select monogenic and hematologic disorders, but off-target mutations, immune responses, delivery constraints, and cost remain substantial barriers to broader adoption. Emerging base and prime editing approaches may reduce some risks but introduce distinct liabilities requiring case-by-case evaluation.
A structured literature review synthesizing current evidence on CRISPR-Cas9 therapeutic applications, identifying clinical advances, translational hurdles, and emerging alternatives without reporting original trial data or effect sizes.
As stated by the source record.
Clinicians and researchers should recognize that CRISPR-Cas9 has demonstrated early clinical efficacy in select monogenic and hematologic disorders, but off-target mutations, immune responses, delivery constraints, and cost remain substantial barriers to broader adoption. Emerging base and prime editing approaches may reduce some risks but introduce distinct liabilities requiring case-by-case evaluation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
CRISPR-Cas9, adapted from the bacterial Type II CRISPR adaptive immune system, functions as a programmable RNA-guided endonuclease that employs a single-guide RNA to direct Cas9 to specific genomic loci. CRISPR-Cas9 has transformed targeted genome editing by replacing complex protein engineering with programmable Watson–Crick base pairing between the guide RNA and target DNA. This review was developed following a structured literature search of major biomedical databases and clinical trial registries to synthesize current evidence on the therapeutic applications of CRISPR-Cas9 in oncology and inherited genetic disorders. Clinical studies of ex vivo BCL11A -enhancer editing have shown fetal hemoglobin reactivation, with most evaluable participants with sickle cell disease remaining free of severe vaso-occlusive crises for the prespecified period and most evaluable participants with transfusion-dependent β-thalassemia achieving sustained transfusion independence. In vivo reductions in circulating transthyretin protein levels have been achieved for transthyretin amyloidosis via lipid nanoparticle delivery, while clinically meaningful improvements in selected measures of visual function were observed in a subset of patients receiving subretinal AAV-delivered CRISPR editing for CEP290 -associated Leber congenital amaurosis type 10. Preclinical and early clinical studies have further investigated CRISPR-engineered T cells designed to improve antitumor activity, persistence, or resistance to inhibitory signaling. Despite these advances, key translational hurdles include the risk of off-target mutations and large-scale chromosomal rearrangements. Furthermore, immune responses against bacterial Cas9 nucleases and viral delivery vectors may limit the long-term efficacy of CRISPR-based therapies, while technical barriers surrounding delivery to extrahepatic tissues, such as skeletal muscle and the central nervous system, continue to hinder broader clinical success. Ethical concerns regarding germline modifications and the high cost of individualized therapies present additional translational challenges. Consequently, emerging DSB-independent technologies, such as base editing and prime editing, may reduce selected DSB-associated liabilities, but each introduces distinct editing, delivery, and genotoxicity risks that require product-specific evaluation.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.